Cargando…

Preclinical study of CD19 detection methods post tafasitamab treatment

INTRODUCTION: Several CD19 targeted antibody-based therapeutics are currently available for patients with diffuse large B-cell lymphoma (DLBCL), including the Fc-modified antibody immunotherapy tafasitamab. This therapeutic landscape warrants the evaluation of potential sequencing approaches. Prior...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ilieva, Kristina, Eberl, Markus, Jaehrling, Jan, Blair, Derek, Patra-Kneuer, Maria, Boxhammer, Rainer, Alvarez Arias, Diana, Heitmüller, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622958/ https://www.ncbi.nlm.nih.gov/pubmed/37928552 http://dx.doi.org/10.3389/fimmu.2023.1274556

Ejemplares similares

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY
por: Arora, Arshi, et al.
Publicado: (2023)

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
por: Her, Jung Hyun, et al.
Publicado: (2022)

The use of tafasitamab in diffuse large B-cell lymphoma
por: Düll, Johannes, et al.
Publicado: (2021)

Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice
por: Migotto, Mary-Anne, et al.
Publicado: (2019)

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration
por: Torres, Julia Baguña, et al.
Publicado: (2022)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report
por: Nasir, Syed Alishan, et al.
Publicado: (2022)

Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia
por: Wu, Gongqiang, et al.
Publicado: (2023)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
por: Roster, Katie, et al.
Publicado: (2023)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer
por: Yasmin-Karim, Sayeda, et al.
Publicado: (2018)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
por: Rosenthal, Allison, et al.
Publicado: (2023)

Xenotransplantation: Current Status in Preclinical Research
por: Lu, Tianyu, et al.
Publicado: (2020)

Preclinical models and evaluation criteria of prostatitis
por: He, Hailan, et al.
Publicado: (2023)

Analysis of T cell repertoires of CD45RO CD4 T cells in cohorts of patients with bullous pemphigoid: A pilot study
por: Niebuhr, Markus, et al.
Publicado: (2022)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

The significance of preclinical anti-BP180 autoantibodies
por: Mai, Yosuke, et al.
Publicado: (2022)

Editorial: Preclinical macaque models of viral diseases
por: Smedley, Jeremy
Publicado: (2023)

Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
por: Fantini, Massimo, et al.
Publicado: (2018)

When Aging Reaches CD4+ T-Cells: Phenotypic and Functional Changes
por: Moro-García, Marco Antonio, et al.
Publicado: (2013)

Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19
por: Agurto-Arteaga, Andres, et al.
Publicado: (2022)

An Unusual MHC Molecule Generates Protective CD8+ T Cell Responses to Chronic Infection
por: Tsitsiklis, Alexandra, et al.
Publicado: (2020)

Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study
por: Rovin, Brad H., et al.
Publicado: (2022)

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
por: Belada, D., et al.
Publicado: (2022)

Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis
por: Prezzemolo, Teresa, et al.
Publicado: (2014)

Human γδ T-Cell Control of Mucosal Immunity and Inflammation
por: McCarthy, Neil E., et al.
Publicado: (2018)

Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys
por: Theil, Diethilde, et al.
Publicado: (2019)

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
por: Carotta, Sebastian
Publicado: (2016)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020)

Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
por: Chu, Wing Sum, et al.
Publicado: (2021)

Progress in preclinical studies of macrophage autophagy in the regulation of ALI/ARDS
por: Liu, Chang, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

Editorial: Imaging the immune response in inflammatory preclinical in vivo models
por: Erreni, M., et al.
Publicado: (2023)

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023)

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
por: Nowakowski, Grzegorz S., et al.
Publicado: (2022)

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY
por: Duell, Johannes, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0h8289pcglvfqgfmagk0bh29mg